Zechnich A D, Greenlick M, Haxby D, Mullooly J
Department of Emergency Medicine, Oregon Health Sciences University, Portland 97201, USA.
Med Care. 1998 Aug;36(8):1283-94. doi: 10.1097/00005650-199808000-00015.
To reduce program costs, the Oregon Medicaid program eliminated reimbursement for over-the-counter (OTC) medications. Considering that physicians might substitute more expensive prescription-only products for eliminated OTC therapy, this investigation evaluates the policy's impact on medication costs.
This retrospective investigation examines pharmacy claims for adult Medicaid eligible recipients between March 1992 and February 1994 using an interrupted time-series analysis. The policy's impact on program costs and on the number of submitted claims was evaluated separately for prescription-only and total prescribing in nine therapeutic categories.
In the preintervention period, OTC products comprised 36% (213,516 of 592,672) of drug claims and 9% ($1.36 million of $14.58 million) of medication costs in the nine therapeutic categories. Decreased program costs were noted in five categories and no significant changes were found in four others; overall, medication costs decreased from $7.86 to $7.39 per eligible recipient per month. A significant increase in prescription-only prescribing was noted in the hematinics category, but the net effect on total costs demonstrated a significant decrease.
The OTC elimination policy was successful in reducing program drug costs with limited evidence for substitution of prescription-only products. Further study is needed to determine the impact on patients who regularly received OTC medications and to evaluate secondary effects on outpatient visits, hospitalization, and clinical outcomes.
为降低项目成本,俄勒冈医疗补助计划取消了非处方药(OTC)的报销。鉴于医生可能会用更昂贵的处方药替代已取消的非OTC治疗,本调查评估了该政策对药物成本的影响。
本回顾性调查采用间断时间序列分析,研究了1992年3月至1994年2月期间符合医疗补助条件的成年患者的药房报销申请。分别评估了该政策对九个治疗类别的处方药和总处方的项目成本及提交申请数量的影响。
在干预前阶段,九个治疗类别中的非处方药产品占药品申请的36%(592,672份申请中的213,516份),占药物成本的9%(1458万美元中的136万美元)。五个类别中项目成本有所下降,其他四个类别未发现显著变化;总体而言,每位符合条件的患者每月的药物成本从7.86美元降至7.39美元。补血剂类别中仅处方药的处方量显著增加,但对总成本的净影响显示出显著下降。
非处方药取消政策成功降低了项目药物成本,仅有有限证据表明存在用处方药替代的情况。需要进一步研究以确定对经常使用非处方药的患者的影响,并评估对门诊就诊、住院和临床结局的次要影响。